At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8 enrolled
Drug / intervention
PCV 13biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted May 13, 2013·Updated Feb 2, 2017
In Brief
A clinical study evaluating PCV 13 for Multiple Myeloma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMay 2013
Primary CompletionFeb 2015
Study CompletionOct 2016
TodayJul 2026
First PostedMay 13, 2013
Enrollment StartFeb 1, 2013
Primary CompletionFeb 1, 2015
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.1 years ago
Interventions
PCV 13biological